JP6240155B2 - 経口ワクチン投与のための改善アジュバント系 - Google Patents
経口ワクチン投与のための改善アジュバント系 Download PDFInfo
- Publication number
- JP6240155B2 JP6240155B2 JP2015504545A JP2015504545A JP6240155B2 JP 6240155 B2 JP6240155 B2 JP 6240155B2 JP 2015504545 A JP2015504545 A JP 2015504545A JP 2015504545 A JP2015504545 A JP 2015504545A JP 6240155 B2 JP6240155 B2 JP 6240155B2
- Authority
- JP
- Japan
- Prior art keywords
- adjuvant
- antigen
- aluminum
- ctl
- eudragit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261686372P | 2012-04-04 | 2012-04-04 | |
US61/686,372 | 2012-04-04 | ||
PCT/US2013/000102 WO2013151595A1 (fr) | 2012-04-04 | 2013-04-03 | Système adjuvant amélioré pour vaccin administré par voie orale |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015512441A JP2015512441A (ja) | 2015-04-27 |
JP2015512441A5 JP2015512441A5 (fr) | 2015-09-17 |
JP6240155B2 true JP6240155B2 (ja) | 2017-11-29 |
Family
ID=49300897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015504545A Active JP6240155B2 (ja) | 2012-04-04 | 2013-04-03 | 経口ワクチン投与のための改善アジュバント系 |
Country Status (10)
Country | Link |
---|---|
US (3) | US20150079130A1 (fr) |
EP (2) | EP3549605A1 (fr) |
JP (1) | JP6240155B2 (fr) |
KR (1) | KR101867428B1 (fr) |
AU (1) | AU2013243971B2 (fr) |
CA (1) | CA2903313C (fr) |
DK (1) | DK2833914T3 (fr) |
IL (1) | IL234937B (fr) |
MX (1) | MX364946B (fr) |
WO (1) | WO2013151595A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL247301B (en) * | 2014-02-20 | 2022-07-01 | Vaxart Inc | Formulations for administration to the small intestine |
EP3185896A4 (fr) * | 2014-06-20 | 2018-03-07 | University of Saskatchewan | Compositions d'exotoxine/thermolysine et méthodes et utilisations pour le traitement ou la prévention de la fourbure |
EP3426290A1 (fr) * | 2016-03-07 | 2019-01-16 | GlaxoSmithKline Biologicals SA | Particules destinées à l'administration de médicament |
KR102369740B1 (ko) | 2020-09-21 | 2022-03-02 | 부경대학교 산학협력단 | 자궁경부암 조기진단을 위한 모바일 질확대경 장치 |
CN113750228B (zh) * | 2021-09-25 | 2024-02-20 | 大连理工大学 | 一种冷冻保护剂在铝佐剂中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4133397A (en) * | 1996-10-28 | 1998-05-22 | Pfizer Inc. | Oral vaccines for young animals with an enteric coating |
CA2280839A1 (fr) * | 1997-02-14 | 1998-08-20 | Merck & Co., Inc. | Formules de vaccins a base de polynucleotides |
US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
US20030162955A1 (en) * | 1998-03-17 | 2003-08-28 | Lionel Chalus | Isolated mammalian membrane protein genes; related reagents |
EP1637154A3 (fr) * | 1998-07-08 | 2007-08-15 | Kirin-Amgen Inc. | Poudre contenant un principe actif d'un haut poids moléculaire à l'administration par les muqueuses |
EP1046651A1 (fr) * | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition et méthode pour moduler l'interaction des cellules dendritiques et les cellules T |
MXPA05001953A (es) * | 2002-08-20 | 2005-06-22 | Genitrix Llc | Composiciones de lecitina y metodos para modular una respuesta inmune a un antigeno. |
US20040213745A1 (en) * | 2003-02-20 | 2004-10-28 | Vincent Sullivan | Powder formulations of rSEB for improved vaccination |
GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
AU2007300543A1 (en) * | 2006-09-26 | 2008-04-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for enhancing an adjuvant |
CN102573802A (zh) * | 2009-08-12 | 2012-07-11 | 希格默伊德药业有限公司 | 包含聚合物基质和油相的免疫调节组合物 |
GB0919690D0 (en) * | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
GB201101665D0 (en) * | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
-
2013
- 2013-04-03 MX MX2014011806A patent/MX364946B/es active IP Right Grant
- 2013-04-03 CA CA2903313A patent/CA2903313C/fr active Active
- 2013-04-03 WO PCT/US2013/000102 patent/WO2013151595A1/fr active Application Filing
- 2013-04-03 EP EP19151134.4A patent/EP3549605A1/fr active Pending
- 2013-04-03 AU AU2013243971A patent/AU2013243971B2/en not_active Ceased
- 2013-04-03 EP EP13772028.0A patent/EP2833914B1/fr active Active
- 2013-04-03 DK DK13772028.0T patent/DK2833914T3/en active
- 2013-04-03 KR KR1020147030919A patent/KR101867428B1/ko active IP Right Grant
- 2013-04-03 US US13/261,964 patent/US20150079130A1/en not_active Abandoned
- 2013-04-03 JP JP2015504545A patent/JP6240155B2/ja active Active
-
2014
- 2014-10-02 IL IL234937A patent/IL234937B/en unknown
-
2018
- 2018-12-06 US US16/212,088 patent/US20190105389A1/en not_active Abandoned
-
2020
- 2020-11-05 US US17/090,292 patent/US20210052725A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL234937A0 (en) | 2014-12-31 |
EP2833914B1 (fr) | 2019-01-16 |
CA2903313C (fr) | 2019-10-22 |
EP2833914A1 (fr) | 2015-02-11 |
US20210052725A1 (en) | 2021-02-25 |
US20150079130A1 (en) | 2015-03-19 |
JP2015512441A (ja) | 2015-04-27 |
KR101867428B1 (ko) | 2018-07-19 |
DK2833914T3 (en) | 2019-03-11 |
AU2013243971B2 (en) | 2017-01-05 |
MX2014011806A (es) | 2015-06-03 |
US20190105389A1 (en) | 2019-04-11 |
KR20150002755A (ko) | 2015-01-07 |
WO2013151595A1 (fr) | 2013-10-10 |
EP3549605A1 (fr) | 2019-10-09 |
MX364946B (es) | 2019-05-15 |
CA2903313A1 (fr) | 2013-10-10 |
IL234937B (en) | 2021-10-31 |
AU2013243971A1 (en) | 2014-10-02 |
EP2833914A4 (fr) | 2016-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210052725A1 (en) | Adjuvant system for oral vaccine administration | |
US20070237826A1 (en) | Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides | |
KR101960102B1 (ko) | 비강내 전달을 위한 방법 및 조성물 | |
WO2010050578A1 (fr) | Vaccin mucosal utilisant un nanogel cationique | |
CN111278458A (zh) | 佐剂疫苗 | |
US20220249646A1 (en) | Composition and method for spray drying an adjuvant vaccine emulsion | |
EP2040749A2 (fr) | Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium | |
Dahhas et al. | Role of site-directed mutagenesis and adjuvants in the stability and potency of anthrax protective antigen | |
US9216215B2 (en) | Adjuvant system for vaccine adjuvant | |
US20200405849A1 (en) | Vaccine system for vaccine adjuvant | |
Prajapati et al. | In-Vitro And In-Vivo Assessment of Antigen-Encapsulated Dextran Nanoparticles | |
Rosales-Mendoza et al. | Silica-based mucosal nanovaccines | |
Valiveti | Polymeric Nanovaccine Delivery System for Influenza Vaccine | |
Hassett | Ultra stable glassy state vaccines containing adjuvants | |
Hassett et al. | Formulation Approaches and Strategies for Vaccines and Adjuvants | |
Lu | EVALUATION OF ALPHA-D-GLUCAN NANOPARTICLE AS A VACCINE ADJUVANT | |
Gregory | Investigating the use of gold nanoparticles in vaccine delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150731 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161128 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170626 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170724 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171003 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171102 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6240155 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |